Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Bayer ONYX Pharmaceuticals |
---|---|
Information provided by: | Bayer |
ClinicalTrials.gov Identifier: | NCT00101413 |
The purpose of the study is to evaluate if BAY 43-9006 has an effect on the tumors, how long the effect continues, if the patients receiving BAY 43-9006 will live longer.
Condition | Intervention | Phase |
---|---|---|
Cancer Carcinoma, Non-Small Cell Lung |
Drug: Nexavar (Sorafenib, BAY 43-9006) |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Phase II Multicenter Uncontrolled Trial of BAY 43-9006 in Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Carcinoma |
Enrollment: | 54 |
Study Start Date: | April 2004 |
Study Completion Date: | April 2008 |
Primary Completion Date: | June 2005 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Arm 1: Experimental |
Drug: Nexavar (Sorafenib, BAY 43-9006)
BAY 43-9006 400 mg bid X 28 day cycles [Continuous treatment for max 2 years; potential for compassionate use study thereafter and long term survival follow-up post drug d/c]
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Texas | |
Houston, Texas, United States, 77030 | |
Germany, Schleswig-Holstein | |
Großhansdorf, Schleswig-Holstein, Germany, 22927 |
Study Director: | Bayer Study Director | Bayer |
Responsible Party: | Bayer HealthCare AG ( Therapeutic Area Head ) |
Study ID Numbers: | 100557 |
Study First Received: | January 10, 2005 |
Last Updated: | November 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00101413 |
Health Authority: | United States: Food and Drug Administration |
NSCLC |
Thoracic Neoplasms Non-small cell lung cancer Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Sorafenib Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Molecular Mechanisms of Pharmacological Action |
Antineoplastic Agents Therapeutic Uses Enzyme Inhibitors Protein Kinase Inhibitors Pharmacologic Actions |